The study, which included 1,074 patients, found that the chemotherapy-free regimen outperformed the current standard care, osimertinib, in extending patient survival, according to a Jan. 7 news release from the company.
The combination showed a median overall survival improvement of over one year compared to osimertinib, marking the first such survival benefit in this patient group.
Overall survival, which measures the length of time patients live after starting treatment, is considered the most meaningful endpoint in cancer treatment. These results follow earlier data from the trial showing improved progression-free survival.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.